This Month's Profile Group: Diabetes Drug Development, Seeing Light In The Dark Ages?, features profiles of Ember Therapeutics, Metabolic Solutions, NovaTarg and Thermalin Diabetes. Plus these Start-Ups Across Health Care: HepatoChem, Nimbic Systems, Pherecydes Pharma and Vascular Access Technologies.
You may also be interested in...
Protecting surgical incision sites from bacteria that cause infection is an ongoing challenge for implant surgeons. Older technologies, such as laminar flow (the distribution of filtered air) and body exhaust suits offer debatable benefit. But the new Air Barrier System from Nimbic Systems Inc. has demonstrated reductions of infection-causing bacteria at incisions by up to 84%, thanks to its ability to create a high-purity, non-turbulent zone of protective air over the surgical site, thus preventing bacteria from entering the patient’s body.
Central venous access continues to be linked to an abnormally high risk of serious and life-threatening complications. Unintended damage to major organs results from the “blind” placement of a hollow needle through the patient’s skin and into the target vein. Vascular Access Technologies Inc. hopes to reduce complications with SAFECVAD, a novel steerable catheter that uses the femoral vein as its point of entry. It is observed under fluoroscopy as it follows a simple guided path to the jugular or subclavian vein, where it makes a visible “inside-out” exit at the exact desired location for central line catheter placement.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)